REGINfo: GALAPAGOS - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$GALAPAGOS: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2020.06.05 | 22:01 | Permanent Information Releases / General Company News

puce NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS - HTML (w)

2020.06.05 | 22:01 | Permanent Information Releases / General Company News

puce NIEUWE ANALYSES VAN HET FASE 2 EQUATOR-KLINISCHE PROGRAMMA ONDERSTEUNEN DE DUURZAME WERKZAAMHEID VAN FILGOTINIB BIJ PSORIATISCHE ARTRITIS - HTML (w)

2020.06.04 | 07:00 | Permanent Information Releases / General Company News

puce FILGOTINIB DEMONSTRATES DURABLE EFFICACY AND CONSISTENT SAFETY PROFILE AT 52 WEEKS IN FINCH 1 AND 3 STUDIES IN RHEUMATOID ARTHRITIS - HTML (w)

2020.06.04 | 07:00 | Permanent Information Releases / General Company News

puce FILGOTINIB LAAT EEN DUURZAAM & CONSISTENT WERKZAAMHEIDS- EN VEILIGHEIDSPROFIEL ZIEN IN DE FINCH 1 EN FINCH 3 52 WEKEN REUMASTUDIES - HTML (w)

2020.05.28 | 22:01 | Permanent Information Releases / Operations

puce Galapagos increases share capital through subscription right exercises - HTML (w)

2020.05.28 | 22:01 | Permanent Information Releases / Operations

puce Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten - HTML (w)

2020.05.20 | 22:01 | Permanent Information Releases / General Company News

puce GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS - HTML (w)

2020.05.20 | 22:01 | Permanent Information Releases / General Company News

puce GILEAD EN GALAPAGOS KONDIGEN POSITIEVE RESULTATEN AAN VAN FASE 2B/3-STUDIE MET FILGOTINIB VOOR DE BEHANDELING VAN MATIGE TOT ERNSTIGE COLITIS ULCEROSA - HTML (w)

2020.05.07 | 22:03 | Permanent Information Releases / Sales and Revenues

puce On track for clinical read-outs and commercial readiness in 2020 - HTML (w)

2020.05.07 | 22:03 | Permanent Information Releases / Sales and Revenues

puce Op schema voor klinische resultaten en commerciële gereedheid in 2020 - HTML (w)

2020.05.07 | Periodic information / 1st Quarter Information

puce GALAPAGOS : Q1 Report 2020 - PDF (678Kb)

2020.05.07 | Periodic information / 1st Quarter Information

puce GALAPAGOS : Verslag eerste kwartaal 2020 - PDF (663Kb)

2020.04.17 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos creates new subscription right plans - HTML (w)

2020.04.17 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos creëert nieuwe inschrijvingsrechtenplannen - HTML (w)

2020.04.17 | 01:04 | Permanent Information Releases / General Company News

puce Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 244